Pharma firm Glenmark on Monday said it had settled all pending patent disputes with U.S.-based Medicis Pharmaceutical Corp over a skin disease drug, besides signing a licensing agreement for new drug delivery system (NDDS).

The company through its U.S.-based subsidiary Glenmark Generics has announced the settlement of all litigation pending between Medicis and Glenmark related to the generic version of Vanos and Loprox gel, used in the treatment in dermatology therapeutic area, Glenmark spokesperson told PTI.

More In: Companies | Business